Key Drivers
- Debt Surge
- Margin Pressure
- Liquidity Decline
AIAI Summary
BioMarin's investment case now hinges less on VOXZOGO-led growth and more on whether Amicus integration delivers $200–$220 million in synergies, sustained free-cash-flow growth, and deleveraging; with $4.19 billion of debt and a premium valuation, investors should demand proof of cash conversion and improving interest coverage before underwriting further upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Debt Surge
- •Margin Pressure
- •Liquidity Decline
BMRN's strong margins and positive cash flow are offset by sharply higher debt, weaker net profitability, and elevated valuation, making deleveraging and earnings recovery key watchpoints.
Price Behavior
Key Price Behavior Insights:
- •Below moving average
- •Support breakdown
- •Resistance rejection
BMRN is bearish over the last month, with a break below $64–$64.50 support signaling downside risk unless it reclaims $66.40 resistance.
Repeated rejection near $66.40–$67.00 preceded the support break
Sentiment & News
Key News Insights:
- •Royalty settlement
- •Pipeline expansion
- •VOXZOGO progress
BioMarin strengthened its rare-disease growth outlook through pipeline expansion, VOXZOGO progress, and royalty upside, despite discontinuing its Noonan syndrome program.
The updates are broadly positive for BioMarin's growth profile, supported by new assets and expanded commercial opportunities
Similar Companies in Healthcare
Other companies in the same sector with AI ratings